| Literature DB >> 30355114 |
Vasileios-Arsenios Lioutas1, Nitin Goyal2, Aristeidis H Katsanos3,4, Christos Krogias5, Ramin Zand6, Vijay K Sharma7, Panayiotis Varelas8, Konark Malhotra9, Maurizio Paciaroni10, Aboubakar Sharaf11, Jason Chang12, Theodore Karapanayiotides13, Odysseas Kargiotis14, Alexandra Pappa2,15, Jeffrey Mai16, Abhi Pandhi, Christoph Schroeder5, Argyrios Tsantes17, Chandan Mehta8, Ali Kerro2, Ayesha Khan6, Panayiotis D Mitsias8,18, Magdy H Selim1, Andrei V Alexandrov2, Georgios Tsivgoulis2,3.
Abstract
Background and Purpose- The aim of this study was to prospectively validate our prior findings of smaller hematoma volume and lesser neurological deficit in nonvitamin K oral anticoagulant (NOAC) compared with Vitamin K antagonist (VKA)-related intracerebral hemorrhage (ICH). Methods- Prospective 12-month observational study in 15 tertiary stroke centers in the United States, Europe, and Asia. Consecutive patients with premorbid modified Rankin Scale score of <2 with acute nontraumatic anticoagulant-related ICH divided into 2 groups according to the type of anticoagulant: NOAC versus VKA. We recorded baseline ICH volume, significant hematoma expansion (absolute [12.5 mL] or relative [>33%] increase), neurological severity measured by National Institutes of Health Stroke Scale score, 90-day mortality, and functional status (modified Rankin Scale score). Results- Our cohort comprised 196 patients, 62 NOAC related (mean age, 75.0±11.4 years; 54.8% men) and 134 VKA related (mean age, 72.3±10.5; 73.1% men). There were no differences in vascular comorbidities, antiplatelet, and statin use; NOAC-related ICH patients had lower median baseline hematoma volume (13.8 [2.5-37.6] versus 19.5 [6.6-52.0] mL; P=0.026) and were less likely to have severe neurological deficits (National Institutes of Health Stroke Scale score of >10 points) on admission (37% versus 55.3%, P=0.025). VKA-ICH were more likely to have significant hematoma expansion (37.4% versus 17%, P=0.008). NOAC pretreatment was independently associated with smaller baseline hematoma volume (standardized linear regression coefficient:-0.415 [95% CI, -0.780 to -0.051]) resulting in lower likelihood of severe neurological deficit (odds ratio, 0.44; 95% CI, 0.22-0.85) in multivariable-adjusted models. Conclusions- Patients with NOAC-related ICH have smaller baseline hematoma volumes and lower odds of severe neurological deficit compared with VKA-related ICH. These findings are important for practicing clinicians making anticoagulation choices.Entities:
Keywords: anticoagulants; brain; dabigatran; rivaroxaban; warfarin
Mesh:
Substances:
Year: 2018 PMID: 30355114 PMCID: PMC6386175 DOI: 10.1161/STROKEAHA.118.021979
Source DB: PubMed Journal: Stroke ISSN: 0039-2499 Impact factor: 7.914